January 09, 2024 BY Elizabeth Anderson
Merck moving forward with $680m Harpoon acquisition
Harpoon has a portfolio of innovative T-cell engagers using the company’s proprietary TriTAC and ProTriRAC platforms to harness and activate a patient’s immune system to eliminate malign cells. During 2023, Harpoon shares climbed by 41% and surged by almost 112% on Monday. Analysts believe Merck is exploring new avenues of growth as its current top-selling…
Read more